Ovarian cancer is characterized as aggressive and usually asymptomatic disease therefore is diagnosed at late-stage, so it is important to look for the best treatment [1]. One promising way is intraperitoneal (IP) chemotherapy. Some studies have demonstrated its survival advantage in comparison to intravenous (IV), although more severe adverse effects have been noticed and it is unknown if it is long-term beneficial [2].
Our aim was to compare outcomes of IP and IV chemotherapy, progression-free survival (PFS) and side effects of drugs.
Methods we used: retrospective study of 36 patients with epithelial ovarian cancer at Vilnius University Hospital Santariskiu Klinikos. 15/36 patients were treated with IP chemotherapy and 21/36 – IV. Analyzed data: demography of patients, cytoreduction rate, tumor differentiation grade, existence of metastasis, influence of neoadjuvant chemotherapy, PFS and drugs' adverse effects. Associations between categorical variables were determined using Shapiro-Wilk test, t-test of independent samples; applications used – Microsoft Excel 2010, SPSS 17.0.
Results: average age of patients: IP – $47.5\pm7.9$ years, IV – $52.8\pm12.4$ years.
| IP (months) | IV (months) | p= | ||
|---|---|---|---|---|
| Statistically significant | Average PFS with neoadjuvant chemotherapy | 13.3±2.5 | 21.5±10.7 | 0.001 |
| Average PFS | 19.5±2.9 | 20.1±4.0 | 0.904 | |
| PFS after radical debulking (R0) | 13,3±2,5 | 23,1±9,3 | 0.679 | |
| No statistical significance | PFS after G3 differentiation grade | 21.8±4.7 | 19.3±4.1 | 0.694 |
| PFS if metastatic disease | 12 | 13.6±1.8 | - | |
| PFS with no neoadjuvant chemotherapy | 28.8±4.2 | 19.6±4.1 | 0.133 |
To sum up: based on results, there were no statistical significance in both patient's groups average PFS, although treatment starting with neoadjuant chemotherapy is better with IV. Both ways are well tolerated, we did not observe extremely severe side effects.
| More often IP | More often IV | Similar frequency | ||||||
|---|---|---|---|---|---|---|---|---|
| IP (%) | IV (%) | IP (%) | IV (%) | IP (%) | IV (%) | |||
| Drug induced polyneuropathy | 53.3 | 33.3 | Anemia | 46.7 | 71.4 | Cardiotoxicity | 26.7 | 23.8 |
| Neutropenia | 53.3 | 47.6 | Thrombocytopenia | 13.3 | 57.1 | Nephrotoxicity | 6.7 | 9.5 |
| Obstipation | 26.7 | 4.8 | Hepatotoxicity | 0 | 23.8 | Postoperative adhesions | 6.7 | 9.5 |
| Dyspepsia | 46.7 | 28.6 | Arthralgia | 0 | 14.3 | Insomnia | 6.5 | 9.5 |
| Weakness | 20.0 | 9.5 | Rash | 0 | 9.5 | |||
| Abdominal pain | 13.3 | 0 | Ototoxicity | 0 | 4.8 | |||
| Infection at drain site | 13.3 | 0 | Anaphylaxis | 0 | 4.8 | |||
| Headache | 0 | 4.8 | ||||||